Cell cycle-controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation

Edgar Grinstein1, Ying Shan2, Leonid Karawajew3

  • 1Institute of Transplantation Diagnostics and Cellular Therapeutics, Heinrich Heine University Medical Center, 40225 Düsseldorf, Germany.

Insights

Retinoblastoma protein (Rb) suppresses tumors by binding nucleolin, inhibiting human papillomavirus oncogenes. Loss of Rb disrupts this, allowing nucleolin to promote cancer development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Retinoblastoma protein (Rb) is a key tumor suppressor often lost in cancers.
  • Nucleolin, a phosphoprotein in proliferating cells, activates human papillomavirus type 18 (HPV18) oncogenes in cervical cancer.

Purpose of the Study:

  • To investigate the interaction between Retinoblastoma protein (Rb) and nucleolin.
  • To elucidate the role of this interaction in the regulation of HPV18 oncogenes and tumor suppression.

Main Methods:

  • Cell cycle analysis in G1 phase.
  • Co-immunoprecipitation to detect protein-protein interactions.
  • Analysis of DNA binding and gene expression.

Main Results:

  • Nucleolin associates with Rb in G1 phase cells, mediated by Rb's growth-inhibitory domain.
  • Rb binding inhibits nucleolin's DNA binding and interaction with the HPV18 enhancer.
  • Rb loss leads to altered nucleolin localization and contributes to tumor development.

Conclusions:

  • Rb-mediated inhibition of nucleolin's oncogenic activity is a critical tumor suppressive mechanism.
  • Disruption of the Rb-nucleolin interaction due to Rb loss promotes malignant disease progression.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...